Should rituximab be used prior to autologous stem-cell transplantation for non-Hodgkin's lymphoma?

被引：0
作者：
José Rodriguez
机构：
[1] Hospital Son Dureta,member of the Medical Oncology Department
来源：
Nature Clinical Practice Oncology | 2005年 / 2卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：74 / 75
页数：1
相关论文
共 5 条
  • [1] Sharp JG(1996)Outcome of high-dose therapy and autologous transplantation in non-Hodgkin's lymphoma based on the presence of tumor in the marrow or infused hematopoietic harvest J Clin Oncol 14 214-219
  • [2] Kewalramani T(2004)Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma Blood 103 3684-3688
  • [3] Freedman AS(1999)Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma Blood 94 3325-3333
  • [4] Belhadj K(2004)Efficiency of in vivo purging with rituximab prior to autologous peripheral blood progenitor cell transplantation in B-cell non-Hodgkin's lymphoma: a single institution study Ann Oncol 15 504-510
  • [5] Mangel J(2003)Pharmacokinetic study of patients with follicular or mantle cell lymphoma treated with rituximab as 'in vivo purge' and consolidative immunotherapy following autologous stem cell transplantation Ann Oncol 14 758-765
1